May 24, 2019

Announcements

Katie Couric Visits
I was incredibly proud to welcome Katie Couric to Yale Cancer Center and Smilow Cancer Hospital yesterday for our Celebration of Cancer Survivorship. As co-founder of Stand Up to Cancer, Katie began her visit by joining our Phase I Program for their weekly meeting. Lieping Chen presented his latest research endeavors and she was able to meet members of the Phase I team. She then welcomed nearly 400 patients, cancer survivors, and family members to Harkness Auditorium where we discussed her personal story, her advocacy work, cancer screening education, among other causes she champions. The full video of her interview is available on the Smilow Cancer Hospital Facebook page.
Kim Slusser Appointed VP of Patient Services

We are pleased to announce that Kim Slusser, MSN, RN, CHPN, NEA-BC, will join Smilow Cancer Hospital on August 12 as Vice President for Patient Services. Kim is currently the Assistant Vice President and Chief of Oncology Nursing at Duke University Health System. In her role, Kim oversees oncology nursing practice and clinical operations for all oncology services at the health system. Over the last several years, she has worked to advance nursing practice for oncology services and has improved efficiency throughout the clinical delivery system at Duke.

Kim is nationally recognized in her field, and her background in nursing leadership and oncology services will be an asset to our oncology programs on our main campus, at our care centers and across the entire Health System. Please welcome her to Smilow in August.

Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells

ICYMI: Medtech's Precision Oncology Opportunity

May is skin cancer awareness month
New Fellowship Established

I am privileged to announce the establishment of a new fellowship at Yale Cancer Center. Funded by a gift from the Stavros Niarchos Foundation, the Kathryn Louloudis Fund for Early-Career Investigators in Cancer Research, has been developed at Yale Cancer Center, giving us the opportunity to identify a Kathryn Louloudis Fellow in Cancer Research annually, supported by the fund. The Fellowship is named in memory of Kathryn Louloudis, former COO and President of the Foundation. Together with Yale Cancer Center leadership, I will announce the qualifications for the annual fellowship in the coming months and look forward to recognizing our first annual Fellow. I want to extend my great appreciation to the Stavros Niarchos Foundation for their generous support of Yale Cancer Center, and specifically, of our early career scientists.

Yale at ASCO

We are looking forward to another exciting ASCO annual meeting next week and have many of our faculty presenting oral presentations, posters, and leading other scientific sessions. If you are attending, please take time to support your colleagues. A full list of Yale Cancer Center participation can be found on our website. I hope you will also join me, Roy Herbst, and Lori Pickens on Sunday, June 2 at 8:30pm for a reception hosted by Yale Cancer Center and Smilow Cancer Hospital at the Hilton Chicago. Please RSVP.

Engagement Survey

YNHHS faculty and medical staff recently received an email from Press Ganey Associates inviting you to participate in an Engagement Survey on behalf of the Yale New Haven Health System and Yale Medicine. This year's survey is an abbreviated version, focused on tracking levels of engagement from faculty and medical staff throughout our health system.

I encourage you to take the time to complete the survey, and to provide honest and thorough feedback. All responses are confidential. Your feedback is
important so we can appropriately assess needs, evaluate areas for improvement, and plan for our future as an integrated health system. Thank you in advance for your cooperation with this important effort.

Notables

The 2019 Yale Innovation Summit selected eight finalists for funding during this year’s Summit. Of the eight 2019 Blavatnik Awardees, four are Yale Cancer Center members, including Sidi Chen, PhD, a member of our Genetics, Genomics, and Epigenetics Research Program; Anna Pyle, PhD, a member of our Virus and Other Infection-Associated Cancers Research Program; Aaron Ring, MD, PhD, a member of our Cancer Immunology Research Program; and David Spiegel, PhD, MD, a member of our Developmental Therapeutics Research Program. In addition, Demetrios Braddock, MD, PhD, a member of our Genetics, Genomics, and Epigenetics Research Program, took first place in the biotech pitch contest during the Summit.

Congratulations to Michael DiGiovanna, MD, PhD, Associate Professor of Medicine (Medical Oncology) who was awarded the Alvan R. Feinstein Award for outstanding teaching of clinical skills during Yale School of Medicine’s commencement ceremonies this week. Dr. DiGiovanna was recognized for his efforts in the creation of the new medical school curriculum and the excellent feedback received by trainees on his mentorship.

The Lung Cancer Research Foundation (LCRF) announced that Katerina Politi, PhD, a member of our Signal Transduction Research Program, has been named the chair of its Scientific Advisory Board.

At our annual Cancer Center Retreat last week, awards were given for poster presentations in the following categories:

Developing our Phase I Clinical Trial Program is giving our doctors access to new Cancer treatments for our patients to help save lives. #NationalCancerResearchMonth

Read More >>

The section of medical oncology for Smilow Cancer Hospital and our Care Centers gathered earlier this month to celebrate a year’s worth of accomplishments and continued growth, under the leadership of Dr. Roy Herbst, Chief of Medical Oncology. Thank you to our entire team for your dedicated patient care, and commitment to advancing research.

Read More >>

Learn More >>
Basic Research and Computational Science

Yemsratch Akalu (C. Rothlin and S. Ghosh Labs): An eMERging Target in Cancer Immunotherapy

Vincent Cannataro (J. Townsend Lab): Effect sizes of somatic mutations in cancer and the contributions of each mutational signature in tumorigenesis

Translational and Clinical Research

Fernanado de Miguel (K. Politi Lab): BRG1 as a Mediator of Resistance to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Jae Hun Shin (A. Bothwell Lab): DKK2 regulates Lgr5 positive stem cell population during intestinal tumorigenesis and metastasis

Population Science, Prevention & Outcomes Research

Stephanie Prozora (A. Davidoff Lab): Medication Utilization for Symptom Management by Pediatric Inpatients with Cancer at End-of-Life

Yale Cancer Center hosted its annual Trainee Colloquium on Friday, May 17 with 17 podium presentations and 16 poster presentations. Awards were presented to:

Research Excellence Prizes

Dhanusha Nalawansha, PhD, Postdoctoral Associate, MCDB, Mentor: Craig Crews: Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)

Christiane Olivero, PhD Candidate, MCDB, Mentor: Nadia Dimitrova: p53 activates the long noncoding RNA Pvt1b to inhibit Myc and suppress tumorigenesis

Jocelyn Chen, PhD Candidate, Pathology, Mentor: Qin Yan: Identification of epigenetic regulators of breast cancer metastasize to the brain

Kelli Connolly, PhD, Postdoctoral Associate, Immunobiology, Mentor: Nikhil Joshi:

Follow Yale Cancer Center on Twitter

Read in @connecticutmag how our CAR T-Cell Therapy program is helping to save the lives of patients with bloodcancers.

Joan Steitz gave the keynote address to kick off our Splicing Factor Mutations & RNA Biology in Cancer Workshop last night. The conference continues today with a full agenda of presenters from cancer centers across the country.

In first of its kind research @JNCL_Now by @HsiehEvelyn shows diets high in soy foods decrease the risk of bone fractures from osteoporosis in certain breastcancer survivors.

Our thoracic oncology team is presenting the latest targeted options for lungcancer treatment tonight in Westerly for community providers.

@DrRoyHerbstYale discussed creating new types of #clinicaltrials and the need for real time biopsies to fight drug resistance in an recent article in @MedTechStrat

Tune in to Yale Cancer Answers today at 7:30pm on Connecticut Public Radio to listen to Dr. Kelsey Martin discuss hematological concerns while pregnant, and the help hematologists can provide.

Developing our Phase I #ClinicalTrial Program is giving our doctors access to new #cancer treatments for our patients to help save lives.
Investigation of a protective role for PDL-1 on the antitumor potential of CD8+ T cells

Best Poster Award

Helen Beilinson, PhD Candidate, Immunobiology, Mentor: David Schatz: The Role of the N-Terminal Non-core Region of RAG1 in V(D)J Recombination and Lymphocyte Development

Rick Bucala, MD, PhD, a member of Yale Cancer Center’s Cancer Immunology Research Program, has been appointed Chief of the Section of Rheumatology, Allergy & Immunology in Internal Medicine.

Benjamin Kann, MD, a resident in therapeutic radiology, presented Deep Learning Identifies Head and Neck Cancer Extranodal Extension on Preoperative Imaging: External Validation and Radiologist Comparison at the ECOG-ACRIN Annual Spring Meeting on May 2, 2019 in Boston, MA.

Joseph Miccio, MD and Wesley Talcot, MD, residents in therapeutic radiology, presented at the American Radium Society last month. Dr. Miccio presented, Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy +/- Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation. Dr. Talcot presented, Rates of Invasive Carcinoma Following Resection in Patients with Carcinoma-in-situ on Biopsy.

Suzanne Evans, MD, MPH, Associate Professor of Therapeutic Radiology, has been invited by The American Society for Radiation Oncology to serve as Program Vice-chair for the 2019 Best of ASTRO meeting November 15-17 in Washington, DC.

Employee Profile: Al Cabrera

@charlesfuchsmd leads our annual scientific retreat to highlight clinical and research #cancer programs and new initiatives to support patient care.

New research @ScienceTM led by @peterglazer shows how a #cancer drug can help inhibit #DNA repair and one day boost the benefit of treatments for patients.

Join Yale experts for a discussion on acoustic neuroma on June 12 at #Smilow Cancer Hospital with @ANAssociation@YNHH@YaleMed

@DrRoyHerbstYale and @DrBarryBoyd are presenting the latest information on #Immunotherapy treatment and research this evening.

May is #NationalCancerResearchMonth. Check out how CAR T-cell therapy is giving hope to patients with certain #bloodcancers. Our program is the only one in Connecticut!

---

Calendar

Smilow Screening and Prevention Information Table at the Festival of Arts & Ideas

May 25; 12:00 PM
Chapel Street, Criscuolo Park (at Chapel Street and James Street)
Learn More >>

Yale Cancer Answers

May 26; 7:30 PM
WNPR
Understanding Your Pathology Report
Angelique W. Levi, MD
Learn More >>
Not only do medical assistants get patients settled in to their appointment by taking blood pressure readings and measuring for height and weight, many times they are the first impression for a patient when they visit Smilow Cancer Hospital or our Care Centers. Medical assistants set the tone before the doctor enters the room, often putting an anxious patient at ease through conversation or their positive demeanor as they await the doctor's arrival with scan or biopsy results, or for their check-up.

Al Cabrera is one of six medical assistants who work in Smilow Cancer Hospital's 4th floor Multispecialty Center. For the last four years, he has triaged patients as they arrive for appointments, occasionally doing glucose sticks and performing EKGs. He also monitors their morale when they arrive and makes sure to put a smile on their face and turn their day around.

"I try to be compassionate and be a nice person to all," says Al. "I've always been someone who has volunteered and it has been part of my nature to help people."

Cynthia James, BS, CPC, CRHC, Clinical Operations Manager echoes his sentiments, "Al is the backbone of our Medical Assistant staff in our clinic. His colleagues say he is very helpful, reliable, quiet, and an all-around nice guy, and I couldn't agree more."

Al hopes to continue to help people as he awaits acceptance into school to pursue his goal to become an MRI Technician.

Pathology Research in Progress Talks
May 28; 9:30 AM
The Anlyan Center, 1st floor, TAC Auditorium, N-107
Jialing Zhang PhD, MD and Sandra Martinez-Morilla, PhD
Learn More >>

Yale Cancer Center Grand Rounds
May 28; 12:00 PM
55 Park Street, Park Street Auditorium
Antonio Omu, MD and Karla M. Neugebauer, PhD
Learn More >>

Art Therapy and Palliative Care
May 28; 4:30 PM
Smilow Cancer Hospital, NP8 Conference Room
Sticking Together - Young Moms' Collage Group
Learn More >>

Therapeutic Radiology Grand Rounds
May 30; 9:00 AM
Smilow Cancer Hospital at Yale New Haven, North Pavilion, Lower Level (LL), LL505
Using Electronic Medical Record Data to Understand and Improve Healthcare Delivery
Michael S. Leapman, MD
Learn More >>

Immunobiology Seminar Series
May 30; 10:30 AM
The Anlyan Center, 1st floor, TAC Auditorium, N-107
Comparative Approaches Illuminate Immune Regulation of Complex Tissue Regeneration in Mammals
Dr. Ashley Seifert
Learn More >>

Cancer Genetics and Prevention Program Seminar
May 30; 2:30 PM
#OUTOFTHEBLUETHANKS

YCC #OUTOFTHEBLUETHANKS recently recognized the following employees from the Clinical Trials Office: **Jessica Goepfert**, Clinical Trials Team Manager; **Diane Eannotti, RN**, Clinical Research Nurse; **Jazmin Figueroa-Bodine, MD**, Clinical Research Coordinator; and **Katie Wildman**, Clinical Research Assistant.

After receiving word that the Smilow Cancer Hospital Care Center in Trumbull would temporarily closed for two days, these exceptional CTO employees worked diligently to ensure that their research patients could be seen by their provider and team in nearby Smilow Clinics. The rescheduling to other centers required careful coordination with multiple departments including Pharmacy, Nursing, the Clinical Research Support Lab, and Regulatory to ensure that visits were conducted according to applicable protocols, policies, and other regulatory requirements. This team's selfless and conscientious work over a 96-hour period was critical in ensuring that our patients on research trials were comfortable and treated safely, in accordance with study protocols and policies.

Thank you, Jessica, Diane, Jazmin, & Katie!

Yale Cancer Center's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o Anna Raso.
**Funding Opportunities**

**Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models**

Through funds available from the Cancer Moonshot Initiative, and pursuant to the NIH interest in advancing human tissue models that do not rely on human fetal tissue (NOT-OD-19-042), the National Cancer Institute (NCI) is inviting applications for administrative supplements to improve representation of the human immune system in ongoing cancer modeling development projects that can be utilized in immuno-oncology research.

**Application Deadline:** June 3, 2019  
[Learn More >>](#)

**HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trial Not Allowed) (RFA-NS-19-036)**

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers ("hubs") of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in-depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs.

**Application Deadline:** June 3, 2019  
[Learn More >>](#)

**2019 Breast Cancer Alliance Young Investigator Award**

Purpose: To encourage a commitment to breast cancer research, BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator

---

**Brady Memorial Laboratory, Brady Auditorium**

**Coatopathies: Genetic Diseases of Protein Coats**

Juan Bonifacino, PhD

[Learn More >>](#)

**Yale Stem Cell Center Seminar Series**

June 3; 2:00 PM  
The Anlyan Center, 1st floor, TAC Auditorium, N-107

**Relinquishing stemness in early T-cell development: molecular mechanisms and cellular dynamics**

Ellen Rothenberg, PhD

[Learn More >>](#)

**Palliative Care & Symptom Science Research Retreat**

June 4; 8:00 AM  
West Campus, 100 West Campus Drive, Orange, CT

**Moving Forward: Building an Interprofessional Palliative Care Research Center at Yale**

R. Sean Morrison, MD

[Learn More >>](#)

**Pathology Research in Progress Talks**

June 4; 9:30 AM  
The Anlyan Center, 1st floor, TAC Auditorium, N-107

Judit Jimenez-Sainz, PhD and Kristin Zimmerman

[Learn More >>](#)

**Pharmacology Seminar Series**

June 6; 12:30 PM  
Brady Memorial Library, B-131

**Drugging the Undruggable: Therapeutic Targeting of Protein Tyrosine Phosphatases**

[Learn More >>](#)

**Cancer Genetics and Prevention Program Seminar**

June 6; 2:30 PM
Grant. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

**Application Deadline:** June 4, 2019

[Learn More >>](#)

**Biology of Bladder Cancer (R01/R21)**

This FOA encourages applications investigating the biology and underlying mechanisms of bladder cancer.

**Application Deadlines:** (R01): June 5, 2019 (R21): June 16, 2019

[Learn More >>](#)

**Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) (PA-19-200)**

NCI is a participating organization.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields-neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry.

**Application Deadline:** June 5, 2019

[Learn More >>](#)

**Doris Duke Physician Scientist Fellowship**

The Doris Duke Charitable Foundation (DDCF) has announced the creation of the Doris Duke Physician Scientist Fellowship, an inaugural program now open to clinical investigators currently engaged in subspecialty training. Through the Physician Scientist Fellowship, DDCF will aim to encourage emerging physician scientists to pursue careers in clinical research and hopes to promote their transition into faculty-level positions.

**Application Deadline:** June 7, 2019

[Learn More >>](#)
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed) (PAR-19-198)
The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

**Application Deadline:** June 10, 2019

Learn More >>

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) (PAR-19-199)
The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

**Application Deadline:** June 10, 2019

Learn More >>

ITCR: innovative algorithms (R21 Clinical Trial Optional) (RFA-CA-19-038)
The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical,
and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

**Application Deadline:** June 11, 2019 by 5:00pm local time of applicant organization.

[Learn More >>](#)

**Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) (PAR-19-242)**

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, PharmDs, nurses with PhDs, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Application Deadline:** June 18, 2019

[Learn More >>](#)

**Global Oncology Young Investigator Award (GO YIA): Implementation Science to Address Oncology Care in LMICs**

The Conquer Cancer Global Oncology Young Investigator Award (GO YIA) provides research funding to early-career investigators to encourage and promote quality research in global oncology and to develop the next generation researchers to address global health needs.

The project needs to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and also researching the cost of creating sustainable models where they currently do not exist. The ideal grantee will have a mentor who is established, and will need to be within a team or be paired with a high-income
institution working for a period of time in a lower resource setting.

**Application Deadline:** June 27, 2019

[Learn More >>]

**Yale Spore in Skin Cancer Developmental Research Awards and Career Enhancement Awards**

DRA and CEA projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as R01 or equivalent grants.

Developmental Research Program Awards will support a broad spectrum of innovative pilot projects applicable to human skin cancer risk, prevention, diagnosis, prognosis, or treatment.

Career Enhancement Program Awards will support new investigative cutaneous oncologists and other scientists committed to multidisciplinary studies investigating the relevance of biological discoveries in human skin cancer risk, prevention, diagnosis, prognosis or treatment, and enhance the careers of individuals who are already productively investigating this field.

DRP-eligible investigators include established and junior investigators (faculty appointment higher than Postdoctoral Fellow or Research Associate). They include faculty who currently lead skin cancer programs but wish to test an idea clearly distinct from current or pending grants or may lead programs not directed at skin cancer, but be interested in exploring the applicability of their expertise to skin cancer.

CEP funds are often awarded to faculty within five years of appointment as Assistant Professor. Previous recipients of SPORE DRP and CEP funds are generally ineligible to be P.I.s of new projects within 3 years of completion of their previous funding.

**Application Deadline:** July 1, 2019 by 5:00 p.m.

[Learn More >>]
Recent Publications

Quality at the American Society for Radiation Oncology (ASTRO) Annual Meeting: Gender Balance among Invited Speakers and Associations with Panel Success
Elham Rahimy1, Reshma Jagsi2, Henry S. Park3, Jean M. Moran, Laura Cervino4, Ashley Albert, Anna Lee6, Suzanne Evans3
https://doi.org/10.1016/j.ijrobp.2019.05.005
Read More >>

Why Smart Oncology Clinicians do Dumb Things: A Review of Cognitive Bias in Radiation Oncology.
Evans SB, Cain D, Kapur A, Brown D, Pawlicki T.
Pract Radiat Oncol. 2019 Mar 21
Read More >>

High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay.
Tien CJ, Carlson DJ, Nath R, Chen ZJ.
Read More >>

Improving attribution of adverse events in oncology clinical trials.
Read More >>

The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From CancerTherapeutics.
Soufer A, Baldassarre LA.
Read More >>
Risk of unexpected uterine Cancer in women undergoing myomectomy: A population-based study.
Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Schwartz PE, Xu X.
Read More >>

Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma.
Read More >>

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.
Read More >>

Folate-Decorated Polyamidoamine Dendrimer Nanoparticles for Head and Neck Cancer Gene Therapy.
Xu L, Yang H.
Read More >>

Giri S, Huntington SF.
JAMA Oncol. 2019 May 16.
Read More >>

Extracapsular extension is not a significant prognostic indicator in non-squamous cancers of the major salivary glands.
Cheraghlou S, Yu PK, Otremba MD, Mehra S, Yarbrough WG, Judson BL.
Cancers Head Neck. 2018 Jul 3;3:5.
Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas.

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.

Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment.

A Vitamin Pattern Diet Is Associated with Decreased Risk of Gestational Diabetes Mellitus in Chinese Women: Results from a Case Control Study in Taiyuan, China.

NHERF1 is Required for Localization of PMCA2 and Suppression of Early Involution in the Female Lactating Mammary Gland.
**EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.**
[Read More >>](#)

**Role of Surgery in Combination with Immunotherapy.**
[Read More >>](#)

**Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis.**
[Read More >>](#)